Discrepancies between anti-Intereukin5 (anti-IL5) starters from SHARP central registry and eligible patients in clinical trials

Conclusion: Real life indication for anti-IL5 therapy is highly discordant with the RCT eligibility criteria across European countries.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Principe, S., Richards, L. B., Hashimoto, S., Kroes, J. A., Van Bragt, J. J., Vijverberg, S. J., Sont, J. K., Scichilone, N., Bieksiene, K., Brinke, A. T., Csoma, Z., Dahlen, B., Gemicioglu, B., Grisle, I., Kuna, P., Lazic, Z., Mihaltan, F., Popovic-Grle, Tags: 05.02 - Monitoring airway disease Source Type: research